Answers are grounded in this paper and cite their sources.
The SARS-CoV-2 outbreak has necessitated innovation in many areas, including the development of molecular point-of-care tests (POCTs) to facilitate rapid diagnosis. Academia and industry have collaborated to produce these diagnostics at an unparalleled pace, drawing on various methodological approaches. This effort is immediately important in controlling the pandemic, but we argue that it will also create a landscape where near-patient diagnostics become increasingly viable as an approach to rapidly test for human genetic variation. This could result in a new testing paradigm, where genotype is used to routinely tailor management. We make the case that the clinical genetics community is well-placed, given its unique history, to play a central role in the development and implementation of any new testing model.
No takes yet. Share an insight, caveat, or question.
McDermott et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: